Hospital superbug can feed on medical plastic, first-of-its-kind study reveals
A superbug that commonly causes infections in hospitals can feed on plastic used for medical interventions, potentially making it even more dangerous, a world-first study has found.
The bug is a bacteria species called Pseudomonas aeruginosa, which is commonly found in hospital environments and can cause potentially deadly infections in the lungs, urinary tract and blood.
Now, scientists have analyzed a strain of this bacteria from a hospital patient's wound, which revealed a surprising trick that could enable it to persist on surfaces and in patients for longer — its ability to break down the biodegradable plastics used in stints, sutures and implants. The researchers published their findings May 7 in the journal Cell Reports.
"It means we need to reconsider how pathogens exist in the hospital environment," study lead author Ronan McCarthy, a professor in biomedical sciences at Brunel University of London, said in a statement. "Plastics, including plastic surfaces, could potentially be food for these bacteria. Pathogens with this ability could survive for longer in the hospital environment. It also means that any medical device or treatment that contains plastic could be susceptible to degradation by bacteria."
The team's laboratory study raises the need for further research to better understand how this plastic-eating ability affects the bug in realistic hospital environments, in which specific cleaning protocols are in place to help prevent exposing patients and medical instruments to bacteria.
P. aeruginosa is thought to have rapidly evolved over the last 200 years to infect humans as they began living in densely populated areas, especially among those with weakened lungs due to air pollution.
Related: Dangerous 'superbugs' are a growing threat, and antibiotics can't stop their rise. What can?
Since then, many strains of the bug have acquired resistance to a wide variety of antibiotics. These resistant microbes can contaminate catheters and ventilation devices, making P. aeruginosa a common cause of hospital-acquired infections, especially among vulnerable patients. P. aeruginosa is tied to roughly 559,000 deaths per year globally, the majority of which are associated with antimicrobial resistance.
Yet how the bacteria can thrive in ostensibly sterile hospital environments has remained unclear.
To investigate, the researchers took a swab from a patient's wound in a British hospital and analyzed it, which revealed the bug can make an enzyme named Pap1. This enzyme is able to break down the plastic polycaprolactone (PCL) — commonly used in sutures, wound dressings, surgical meshes and other medical equipment — and release the plastic's carbon, which P. aeruginosa can then feed on.
To test whether this enzyme is really responsible for breaking down plastic, the scientists inserted the gene that codes for Pap1 into Escherichia coli bacteria, and found that when that bacteria expressed the enzyme, it too was able to break down PCL. The team further confirmed the enzyme's plastic-eating role when they deleted the gene that codes for it in a P. aeruginosa variant, finding that the microbe was no longer able to dissolve the plastic.
RELATED STORIES
—How fast can antibiotic resistance evolve?
—AI could identify the next superbug-fighting drug
—Scientists have found a secret 'switch' that lets bacteria resist antibiotics — and it's been evading lab tests for decades
The bug's plastic-chewing power doesn't just seem to be granting it a food source: It is also making it more dangerously resistant to treatment. This is because the bacteria uses plastic fragments to form hardier biofilms — structures with protective coatings that shield superbugs from antibiotics — the researchers found.
The scientists also identified similar enzymes in other bacteria, meaning that other widely used medical plastics could be providing sustenance and improved resilience to additional superbugs, possibly contributing to hospital-acquired infections.
To follow up on this, the researchers have called for urgent research on the prevalence of the plastic-eating enzymes among other pathogens, and for experts to reconsider the plastics they use in medical settings, and the ways that they monitor hospital environments.
"Plastic is everywhere in modern medicine, and it turns out some pathogens have adapted to degrade it," McCarthy said. "We need to understand the impact this has on patient safety."
This article is for informational purposes only and is not meant to offer medical advice.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
From Crisis to Comeback: Mbappe's Health Scare Opens New Chapter
French star lost 6kg during Club World Cup illness—but could it actually benefit him? From Crisis to Comeback: Mbappe's Health Scare Opens New Chapter French superstar Kylian Mbappe faced severe health scare during the 2025 FIFA Club World cup but what seemed like setback may turn into unexpected advantage. While representing Real Madrid in the tournament held in the United States Mbappe was rushed to hospital with serious gastrointestinal infection. The illness left him exhausted and forced him to miss multiple games as he recovered under strict medical supervision. According to French outlet L'Equipe, the forward lost around 6 kilogram during the short illness period an observation fans quickly noticed once he returned to action with visibly leaner physique. Despite the alarming weight loss, Mbappe's recovery has been surprisingly quick & efficient thanks to physiological phenomenon known as "muscle memory". Well trained athletes like him can regain lost strength, speed and flexibility more rapidly after temporary decline in physical form. Not the First: Messi's 2014 Lesson Mbappe's case isn't unique. In 2014 Lionel Messi experienced similar struggles due to poor dietary habits. Spanish media revealed that Messi consumed double cheese pizza after games. His form dipped and Cristiano Ronaldo won the Ballon d'or that year. Messi then turned to Italian nutritionist Giuliano Poser , cut out sugar and soda and lost over 3kg in 2015. He bounced back in prime form and reclaimed the Ballon d'Or.
Yahoo
4 hours ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
6 hours ago
- Yahoo
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'